Related Experiment Video

Updated: Jul 5, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells

Kai Gao1, William W Lockwood, Jun Li

  • 1Department of Dermatology and Skin Science, Jack Bell Research Centre, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, Canada.

International Journal of Oncology
|May 24, 2008
PubMed

Insights

Researchers identified new genes linked to camptothecin (CPT) resistance in melanoma. Gains in 14q23.2-31.1 and losses in genome stability genes contribute to CPT resistance, offering potential therapeutic targets.

Area of Science:

  • Genomics
  • Cancer Biology
  • Drug Resistance Mechanisms

Background:

  • Camptothecins (CPTs) like irinotecan are effective in treating cancers, including melanoma.
  • Acquired drug resistance is a major challenge, limiting the long-term efficacy of CPT chemotherapy.
  • The genetic underpinnings of acquired CPT resistance remain largely unknown.

Purpose of the Study:

  • To investigate the genomic alterations associated with acquired camptothecin (CPT) resistance in melanoma.
  • To identify novel genes and chromosomal regions involved in the development of CPT resistance.

Main Methods:

  • Establishment of irinotecan-resistant melanoma cell clones.
  • High-resolution array comparative genomic hybridization (array-CGH) for whole-genome profiling.
  • Quantitative real-time PCR to validate gene expression changes.

Main Results:

  • A novel amplified region was identified at 14q23.2-31.1 in irinotecan-resistant clones.
  • This amplicon contains genes involved in DNA repair, reactive oxygen species management, and transport.
  • Losses were observed at loci of topoisomerases and genes critical for chromosomal stability (e.g., TP53, H2AFX).

Conclusions:

  • Genomic instability plays a significant role in the development of acquired CPT resistance.
  • The identified amplicon at 14q23.3-31.1 presents promising therapeutic targets for overcoming CPT resistance in melanoma.

More Related Videos

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...